Search

Your search keyword '"I.Q. Molenaar"' showing total 78 results
Start Over Author "I.Q. Molenaar"
78 results on '"I.Q. Molenaar"'

1. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)

Author

Iris W. J. M. van Goor, L.A. Daamen, M.G. Besselink, A.M.E. Bruynzeel, O.R. Busch, G.A. Cirkel, B. Groot Koerkamp, N. Haj Mohammad, H.D. Heerkens, H.W.M. van Laarhoven, G.J. Meijer, J. Nuyttens, H.C. van Santvoort, G. van Tienhoven, H.M. Verkooijen, J.W. Wilmink, I.Q. Molenaar, M.P.W. Intven, Surgery, Radiotherapy, Radiation Oncology, CCA - Cancer Treatment and quality of life, Internal medicine, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, and Oncology

Subjects
Isolated local recurrence, SBRT, Medicine (miscellaneous), PDAC, Image-guided radiotherapy, Pancreatic cancer, Radiosurgery, Disease recurrence, Pancreatic Neoplasms, Pancreatic ductal adenocarcinoma, SDG 3 - Good Health and Well-being, Stereotactic body radiation therapy, Quality of Life, Humans, Pituitary Adenylate Cyclase-Activating Polypeptide, Pharmacology (medical), Prospective Studies, Neoplasm Recurrence, Local, Retrospective Studies, Carcinoma, Pancreatic Ductal, SABR
Abstract

Background Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20–30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved local control in these patients, potentially having a beneficial effect on both survival and quality of life. The “nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy” (ARCADE) will investigate the value of SBRT in addition to standard of care in patients with isolated local PDAC recurrence compared to standard of care alone, regarding both survival and quality of life outcomes. Methods The ARCADE trial is nested within a prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the ‘Trials within Cohorts’ design. All PACAP participants with isolated local PDAC recurrence after primary resection who provided informed consent for being randomized in future studies are eligible. Patients will be randomized for local therapy (5 fractions of 8 Gy SBRT) in addition to standard of care or standard of care alone. In total, 174 patients will be included. The main study endpoint is survival after recurrence. The most important secondary endpoint is quality of life. Discussion It is hypothesized that additional SBRT, compared to standard of care alone, improves survival and quality of life in patients with isolated local recurrence after PDAC resection. Trial registration ClinicalTrials.gov registration NCT04881487. Registered on May 11, 2021.

Published
2022

2. Alternative Randomized Trial Designs in Surgery: A Systematic Review

Author

Simone Augustinus, Iris W.J.M. van Goor, Johannes Berkhof, Lois A. Daamen, Bas Groot Koerkamp, Tara M. Mackay, I.Q Molenaar, Hjalmar C. van Santvoort, Helena M. Verkooijen, Peter M. van de Ven, Marc G. Besselink, Surgery, CCA - Cancer Treatment and quality of life, APH - Methodology, Epidemiology and Data Science, Graduate School, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Stepped-wedge, Europe, Surgical research, Registry-based, Randomized controlled trials, Humans, Surgery, Trials-within-cohorts, Randomized Controlled Trials as Topic
Abstract

INTRODUCTION: Randomized controlled trials (RCTs) yield the highest level of evidence but are notoriously difficult to perform in surgery. Surgical RCTs may be hampered by slow accrual, the surgical learning curve, and lack of financial support. Alternative RCT designs such as stepped-wedge randomized controlled trials (SW-RCTs), registry-based randomized controlled trials (RB-RCTs), and trials-within-cohorts (TwiCs) may overcome several of these difficulties. This review provides an overview of alternative RCT designs used in surgical research. METHODS: We systematically searched PubMed, EMBASE, and Cochrane Central for surgical SW-RCTs, RB-RCTs, and TwiCs. A surgical RCT was defined as a randomized trial that studied interventions in patients undergoing general surgery, regardless of the affiliation of the corresponding author. Exponential regression analysis was performed to assess time trends. RESULTS: Overall, 41 surgical RCTs using alternative designs were identified, including 17 published final RCT reports and 24 published protocols of ongoing RCTs. These included 25 SW-RCTs (61%), 13 RB-RCTs (32%), and 3 TwiCs (7%). Most of these RCTs were performed in Europe (63%) and within gastrointestinal/oncological surgery (41%). The total number of RCTs using alternative designs exponentially increased over the last 7 years ( P

Published
2022

3. Stepwise implementation of robotic surgery in a high volume HPB practice in the Netherlands

Author

Inne H.M. Borel Rinkes, Wouter W. te Riele, Jeroen Hagendoorn, I.Q. Molenaar, Hjalmar C. van Santvoort, and Carolijn L.M.A. Nota

Subjects
medicine.medical_specialty, Post hoc, Operative Time, 030230 surgery, Liver resections, Pancreaticoduodenectomy, Resection, 03 medical and health sciences, 0302 clinical medicine, Robotic Surgical Procedures, Humans, Medicine, Robotic surgery, Netherlands, Retrospective Studies, Hepatology, business.industry, General surgery, technology, industry, and agriculture, Gastroenterology, body regions, surgical procedures, operative, 030220 oncology & carcinogenesis, Operative time, business, human activities
Abstract

Background Aims of this study were to describe the stepwise implementation and expansion of robotic HPB surgery in a high volume HPB unit in the Netherlands and to analyze clinical outcomes of all robotic liver resections and robotic pancreatoduodenectomies performed within this program. Methods After proctoring by expert international surgeons, HPB surgeons were introduced to robotic liver resection and robotic pancreatoduodenectomy in a stepwise fashion. Data from two prospective databases containing all consecutive patients who underwent robotic liver resection or robotic pancreatoduodenectomy between August 1st, 2015 and March 1st, 2019 were analyzed post hoc. Results In total, 77 consecutive robotic liver resections and 68 consecutive robotic pancreatoduodenectomies were performed. Five surgeons were consecutively introduced to robotic HPB surgery. Mean operative time for robotic liver resection was 160 ± 78 min. Mean operative time for robotic pancreatoduodenectomy was 420 ± 67 min. Operative times remained stable over time and were not affected by the introduction of new surgeons. Conclusion Stepwise implementation and expansion of robotic HPB surgery within one unit over a three-and-half year period is feasible and associated with good clinical outcomes. Despite introducing new surgeons to the technique, operative times, an indicator of the learning process, remained stable over time.

Published
2020

4. Pancreatic exocrine insufficiency following pancreatoduodenectomy: A prospective bi-center study

Author

V.J. Kroon, L.A. Daamen, D.S.J. Tseng, A. Roele- de Vreugd, L.J.H. Brada, O.R. Busch, T.C. Derksen, A. Gerritsen, S.J.E. Rombouts, F.J. Smits, M.S. Walma, R.A.W. Wennink, M.G. Besselink, H.C. van Santvoort, I.Q. Molenaar, Surgery, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Hepatology, Endocrinology, Diabetes and Metabolism, pancreatic cancer, Gastroenterology, Pancreatic exocrine insufficiency, Humans, Exocrine Pancreatic Insufficiency, pancreatic surgery, Prospective Studies, pancreatic enzyme replacement therapy, Vitamin A, Pancreas, Pancreaticoduodenectomy
Abstract

BACKGROUND/OBJECTIVES: Pancreatic exocrine insufficiency (PEI) is a common complication following pancreatoduodenectomy (PD) leading to malnutrition. The course of PEI and related symptoms and vitamin deficiencies is unknown. This study aimed to assess the (long-term) incidence of PEI and vitamin deficiencies after PD. METHODS: A bi-centre prospective observational cohort study was performed, including patients who underwent PD for mainly pancreatic and periampullary (pre)malignancies (2014-2018). Two cohorts were formed to evaluate short and long-term results. Patients were followed for 18 months and clinical symptoms were evaluated by questionnaire. PEI was based on faecal elastase-1 (FE-1) levels and/or clinical symptoms. RESULTS: In total, 95 patients were included. After three months, all but three patients had developed PEI and 27/29 (93%) patients of whom stool samples were available showed abnormal FE-1 levels, which did not improve during follow-up. After six months, all patients had developed PEI. During follow-up, symptoms resolved in 35%-70% of patients. Vitamin D and K deficiencies were observed in 48%-79% of patients, depending on the moment of follow-up; 0%-50% of the patients with deficiencies received vitamin supplementation. DISCUSSION: This prospective study found a high incidence of PEI after PD with persisting symptoms in one-to two thirds of all patients. Limited attention was paid to vitamin deficiencies. Improved screening and treatment strategies for PEI and vitamins need to be designed.

Published
2022

5. Hospital variation and outcomes of simultaneous resection of primary colorectal tumour and liver metastases

Author

Myrtle F. Krul, Arthur K.E. Elfrink, Carlijn I. Buis, Rutger-Jan Swijnenburg, Wouter W. te Riele, Cornelis Verhoef, Paul D. Gobardhan, Marcel den Dulk, Mike S.L. Liem, Pieter J. Tanis, J.S.D. Mieog, Peter B. van den Boezem, Wouter K.G. Leclercq, Vincent B. Nieuwenhuijs, Michael F. Gerhards, Joost M. Klaase, Dirk J. Grünhagen, Niels F.M. Kok, Koert F.D. Kuhlmann, Eric R. Manusama, Koop Bosscha, Eric J.T. Belt, Maarten Vermaas, Esther C.J. Consten, N.T. van Heek, Steven J. Oosterling, Marc G.H. Besselink, Marieke T. de Boer, Andries E. Braat, Cornelis H.C. DeJong, Jeroen Hagendoorn, I.Q. Molenaar, Gijs A. Patijn, Hendrik A. Marsman, Frederik J.H. Hoogwater, Surgery, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Value, Affordability and Sustainability (VALUE), Groningen Institute for Organ Transplantation (GIOT), MUMC+: MA Heelkunde (9), and RS: NUTRIM - R2 - Liver and digestive health

Subjects
Liver surgery, medicine.medical_specialty, Time Factors, Treatment sequence, Population, Simultaneous resection, Hospital variation, All institutes and research themes of the Radboud University Medical Center, Preoperative chemotherapy, Medicine, Hepatectomy, Humans, education, Retrospective Studies, education.field_of_study, Hepatology, business.industry, Optimal treatment, Liver Neoplasms, Gastroenterology, Colorectal tumour, Postoperative outcomes, CANCER, Hospitals, Surgery, Population based study, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Colorectal liver metastases, Treatment Outcome, business, Colorectal Neoplasms
Abstract

BACKGROUND: The optimal treatment sequence for patients with synchronous colorectal liver metastases (CRLM) remains uncertain. This study aimed to assess factors associated with the use of simultaneous resections and impact on hospital variation.METHOD: This population-based study included all patients who underwent liver surgery for synchronous colorectal liver metastases between 2014 and 2019 in the Netherlands. Factors associated with simultaneous resection were identified. Short-term surgical outcomes of simultaneous resections and factors associated with 30-day major morbidity were evaluated.RESULTS: Of 2146 patients included, 589 (27%) underwent simultaneous resection in 28 hospitals. Simultaneous resection was associated with age, sex, BMI, number, size and bilobar distribution of CRLM, and administration of preoperative chemotherapy. More minimally invasive and minor resections were performed in the simultaneous group. Hospital variation was present (range 2.4%-83.3%) with several hospitals performing simultaneous procedures more and less frequently than expected. Simultaneous resection resulted in 13% 30-day major morbidity, and 1% mortality. ASA classification ≥3 was independently associated with higher 30-day major morbidity after simultaneous resection (aOR 1.97, CI 1.10-3.42, p = 0.018).CONCLUSION: Distinctive patient and tumour characteristics influence the choice for simultaneous resection. Remarkable hospital variation is present in the Netherlands.

Published
2022

6. Online adaptive MR-guided stereotactic radiotherapy for unresectable malignancies in the upper abdomen using a 1.5T MR-linac

Author

M.P.W. Intven, Lois A. Daamen, William A. Hall, Gerrit A. Meijer, I. van Goor, H.D. Heerkens, Beth Erickson, Helena M. Verkooijen, H.C. van Santvoort, H. Eijkelenkamp, I.Q. Molenaar, and S. de Mol van Otterloo

Subjects
medicine.medical_specialty, Mr linac, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Radiotherapy Planning, Computer-Assisted, Gastroenterology, Hematology, General Medicine, Radiosurgery, Stereotactic radiotherapy, Oncology, Abdominal Neoplasms, Abdomen, medicine, Humans, Radiology, Nuclear Medicine and imaging, Radiology, Prospective Studies, Upper abdomen, business, Mri guided, Radiotherapy, Image-Guided
Abstract

Introduction of online adaptive MR-guided radiotherapy enables stereotactic body radiation therapy (SBRT) of upper abdominal tumors. This study aimed to evaluate the feasibility of MR-guided SBRT on a 1.5 T MR-linac in patients with unresectable upper abdominal malignancies.Patients treated at the UMC Utrecht (April 2019 to December 2020) were identified in the prospective 'Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-linac' (MOMENTUM) study. Feasibility of treatment was arbitrarily defined as an on-table time interval of ≤60 min for75% of delivered fractions and completion of95% of fractions as scheduled, reflecting patient tolerability. Acute treatment-related toxicity was assessed at 3 months of follow-up and graded according to the National Cancer Institute Common Terminology Criteria of Adverse Events version 5.0.Twenty-five consecutive patients with a median follow-up time of 8 (range 4-23) months were treated with 35 Gray (Online adaptive MR-guided SBRT on a 1.5 T MR-linac is feasible and well-tolerated in patients with unresectable upper abdominal malignancies. Dose escalation studies, followed by comparative studies, are needed to determine the optimal radiation dose for irradiation of upper abdominal malignancies.

Published
2021

7. Factors associated with failure to rescue after liver resection and impact on hospital variation: a nationwide population-based study

Author

Arthur K.E. Elfrink, Pim B. Olthof, Rutger-Jan Swijnenburg, Marcel den Dulk, Marieke T. de Boer, J. Sven D. Mieog, Jeroen Hagendoorn, Geert Kazemier, Peter B. van den Boezem, Arjen M. Rijken, Mike S.L. Liem, Wouter K.G. Leclercq, Koert F.D. Kuhlmann, Hendrik A. Marsman, Jan N.M. Ijzermans, Peter van Duijvendijk, Joris I. Erdmann, Niels F.M. Kok, Dirk J. Grünhagen, Joost M. Klaase, Wouter W. te Riele, Carlijn I. Buis, Gijs A. Patijn, Andries E. Braat, Cornelis H.C. Dejong, Frederik J.H. Hoogwater, I.Q. Molenaar, Marc G.H. Besselink, Cornelis Verhoef, Hasan H. Eker, Joost A.B. van der Hoeven, N. Tjarda van Heek, Hans Torrenga, Koop Bosscha, Maarten Vermaas, Esther C.J. Consten, Steven J. Oosterling, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Surgery, Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, Value, Affordability and Sustainability (VALUE), and Groningen Institute for Organ Transplantation (GIOT)

Subjects
Liver surgery, medicine.medical_specialty, TO-RESCUE, Failure to rescue, Patient demographics, Disease, COLORECTAL-CANCER SURGERY, 030230 surgery, Logistic regression, Resection, 03 medical and health sciences, Postoperative Complications, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Risk Factors, Internal medicine, medicine, Humans, Hospital Mortality, HEPATOBILIARY SCINTIGRAPHY, Aged, Aged, 80 and over, COMPLICATIONS, Hepatology, business.industry, MORTALITY, Gastroenterology, medicine.disease, Hospitals, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], Population based study, Failure to Rescue, Health Care, Liver, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, VOLUME, RISK-ASSESSMENT, business
Abstract

Contains fulltext : 245446.pdf (Publisher’s version ) (Closed access) BACKGROUND: Failure to rescue (FTR) is defined as postoperative complications leading to mortality. This nationwide study aimed to assess factors associated with FTR and hospital variation in FTR after liver surgery. METHODS: All patients who underwent liver resection between 2014 and 2017 in the Netherlands were included. FTR was defined as in-hospital or 30-day mortality after complications Dindo grade ≥3a. Variables associated with FTR and nationwide hospital variation were assessed using multivariable logistic regression. RESULTS: Of 4961 patients included, 3707 (74.4%) underwent liver resection for colorectal liver metastases, 379 (7.6%) for other metastases, 526 (10.6%) for hepatocellular carcinoma and 349 (7.0%) for biliary cancer. Thirty-day major morbidity was 11.5%. Overall mortality was 2.3%. FTR was 19.1%. Age 65-80 (aOR: 2.86, CI:1.01-12.0, p = 0.049), ASA 3+ (aOR:2.59, CI: 1.66-4.02, p

Published
2021

11. Surveillance After Surgery for Pancreatic Cancer

Author

Lois A. Daamen, I.Q. Molenaar, and Vincent P. Groot

Subjects
Oncology, medicine.medical_specialty, business.industry, Early detection, Treatment options, Diagnostic test, Disease, medicine.disease, Resection, Quality of life, Pancreatic cancer, Internal medicine, medicine, Ct imaging, business
Abstract

Disease recurrence remains the main cause of mortality in patients who underwent pancreatic cancer resection, with a median post-recurrence survival of only 3–9 months. Recent advancements in pancreatic cancer treatment have resulted in an increased interest in early detection and treatment of pancreatic cancer recurrence. However, the efficacy, timing and impact on quality of life of treatment of pancreatic cancer recurrence is yet unclear. As a result, the value of recurrence-focused surveillance for the early detection and treatment of pancreatic cancer recurrence remains controversial. Nevertheless, a surveillance strategy existing of 3–6 monthly serum CA 19-9 testing and CT imaging is increasingly implemented by pancreatic cancer clinicians worldwide. However, high-quality evidence to support this strategy is lacking, and the search for the optimal surveillance strategy is ongoing. Current research therefore not only focuses on expanding treatment options for pancreatic cancer recurrence, but also on improvement of detection methods and the introduction of promising diagnostic tests, such as liquid biopsies.

Published
2021

12. First Year of the European Registry for Minimally Invasive Pancreatic Surgery (E-MIPS)

Author

Alberto Manzoni, M. D'Hondt, A. Kokkola, S. Gaujoux, Mario Serradilla-Martín, H.C. van Santvoort, M. Luyer, N. van der Heijde, Giuseppe Zimmitti, M. Maglione, Svein Olav Bratlie, S. Sanchez Cabús, B. Groot Koerkamp, G. van der Schelling, D.J. Lips, Patrick Pessaux, Frederik Berrevoet, Francois Regis Souche, A. Coratti, Geert Roeyen, Safi Dokmak, Fernando Burdío, Antonello Forgione, R. Fara, M.G. Besselink, T. Hackert, F. Vissers, Bergthor Björnsson, P.B. van den Boezem, J. Balsells, M. Vito Marino, C. Fristrup, D. Del Pozo, Sebastiaan Festen, Ugo Boggi, M.A. Suarez Muñoz, M. Fatih Can, M. Abu Hilal, Igor Khatkov, Tobias Keck, I.Q. Molenaar, Gabriella Pittau, and O. Saint-Marc

Subjects
medicine.medical_specialty, Hepatology, business.industry, General surgery, Gastroenterology, medicine, business, Pancreatic surgery
Published
2021

13. The treatment and survival of elderly patients with locally advanced pancreatic cancer:A post-hoc analysis of a multicenter registry

Author

R.M. van Dam, I. H. J. T. de Hingh, V. E. de Meijer, Leonie J. M. Mekenkamp, Johanna W. Wilmink, Derk Jan A. de Groot, Martijn R. Meijerink, N. Haj Mohammad, J.F.M. Pruijt, Koop Bosscha, Gijs A. Patijn, M. Los, Lilly J H Brada, H.C. van Santvoort, G.J.M. Creemers, Marco B. Polee, Sebastiaan Festen, Geert A. Cirkel, J. de Vos-Geelen, Emile D. Kerver, I.Q. Molenaar, M.G. Besselink, M. Liem, J. A. Ropela, M.S. Walma, J.W.B. de Groot, Martijn W J Stommel, Surgery, RS: NUTRIM - R2 - Liver and digestive health, MUMC+: MA Heelkunde (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Epidemiologie, Graduate School, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Radiology and nuclear medicine, CCA - Cancer Treatment and quality of life, Internal medicine, VU University medical center, Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, FOLFIRINOX, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Locally advanced pancreatic cancer, Kaplan-Meier Estimate, urologic and male genital diseases, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Elderly, DISPARITIES, Registries, NAB-PACLITAXEL, Aged, 80 and over, OUTCOMES, Incidence (epidemiology), Age Factors, Gastroenterology, Chemoradiotherapy, Induction Chemotherapy, Middle Aged, CHEMOTHERAPY, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, 030211 gastroenterology & hepatology, Best supportive care, medicine.drug, Adult, medicine.medical_specialty, Young Adult, 03 medical and health sciences, AGE, Drug Therapy, Internal medicine, Pancreatic cancer, Post-hoc analysis, medicine, Humans, Aged, Chemotherapy, Hepatology, OLDER PATIENTS, business.industry, ADENOCARCINOMA, medicine.disease, Survival Analysis, Comorbidity, Gemcitabine, Pancreatic Neoplasms, GEMCITABINE, business, COMORBIDITY
Abstract

Contains fulltext : 239089.pdf (Publisher’s version ) (Closed access) BACKGROUND: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have improved in recent years and consequently survival has increased. It is unknown, however, if elderly patients benefit from these improvements in therapy. With the ongoing aging of the patient population and an increasing incidence of pancreatic cancer, this patient group becomes more relevant. This study aims to clarify the association between increasing age, treatment and overall survival in patients with LAPC. METHODS: Post-hoc analysis of a multicenter registry including consecutive patients with LAPC, who were registered in 14 centers of the Dutch Pancreatic Cancer Group (April 2015-December 2017). Patients were divided in three groups according to age (

Published
2021

14. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial

Author

Mathieu D'Hondt, Sebastiaan Festen, Rutger C G Bruijnen, O.M. van Delden, E. M. van der Waal, I.H.J.T. de Hingh, J. A. Ropela, J. de Vos-Geelen, Johanna W. Wilmink, Chung Y. Nio, R.M. van Dam, Derk Jan A. de Groot, Geert Roeyen, J.W.B. de Groot, K.P. van Lienden, N. Haj Mohammad, S. J. Rombouts, O.R.C. Busch, Lilly J H Brada, G.J.M. Creemers, M. Liem, Gijs A. Patijn, J. de Vries, F. Daams, I.Q. Molenaar, V. E. de Meijer, M. S. van Leeuwen, Maartje Los, Leonie J. M. Mekenkamp, M.S. Walma, I. Oulad Abdennabi, P. Ghorbani, Martijn W J Stommel, H.C. van Santvoort, Elizabeth Pando, Emile D. Kerver, I. H. M. Borel Rinkes, J.F.M. Pruijt, R. van Hillegersberg, Koop Bosscha, Frank J. Wessels, Martijn R. Meijerink, Marc G. Besselink, Marco B. Polee, Dutch Pancreatic Cancer Group, Surgery, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, Radiology and nuclear medicine, Internal medicine, MUMC+: MA Heelkunde (9), Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), Institut Català de la Salut, [Walma MS, Rombouts SJ, Brada LJH] Departments of Surgery, Radiology and Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Departments of Surgery, Radiology and Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. [Borel Rinkes IH, Bruijnen RC] Departments of Surgery, Radiology and Medical Oncology, UMC Utrecht Cancer Center and St Antonius Hospital Nieuwegein: Regional Academic Cancer Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. [Bosscha K] Departments of Surgery and Medical Oncology, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands. [Pando E] Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, CCA - Cancer Treatment and Quality of Life, Radiology and Nuclear Medicine, Amsterdam Cardiovascular Sciences, Cancer Center Amsterdam, Laboratory for General Clinical Chemistry, and Oncology

Subjects
Oncology, Medicine (General), Radiofrequency ablation, FOLFIRINOX, SURGERY, medicine.medical_treatment, Locally advanced pancreatic cancer, INTERNATIONAL STUDY-GROUP, Medicine (miscellaneous), 030230 surgery, law.invention, Study Protocol, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Quimioteràpia, Clinical endpoint, Multicenter Studies as Topic, Pharmacology (medical), Overall survival, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], Otros calificadores::/terapia [Otros calificadores], Netherlands, Randomized Controlled Trials as Topic, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Extirpació (Cirurgia), TUMORS, Progression-Free Survival, 030220 oncology & carcinogenesis, SURVIVAL, terapéutica::tratamiento de radiofrecuencia::ablación por radiofrecuencia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.drug, medicine.medical_specialty, CLINICAL-OUTCOMES, Therapeutics::Radiofrequency Therapy::Radiofrequency Ablation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], 03 medical and health sciences, R5-920, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, Pancreatic cancer, Pàncrees - Càncer - Tractament, medicine, Humans, Chemotherapy, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], business.industry, Cancer, ADENOCARCINOMA, Other subheadings::/therapy [Other subheadings], medicine.disease, PHASE-III, Gemcitabine, Pancreatic Neoplasms, DEFINITION, GEMCITABINE, Human medicine, business
Abstract

Background Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency ablation (RFA) have reported a promising overall survival of 26–34 months when given in a multimodal setting. However, randomized controlled trials (RCTs) investigating the effect of RFA in combination with chemotherapy in patients with LAPC are lacking. Methods The “Pancreatic Locally Advanced Unresectable Cancer Ablation” (PELICAN) trial is an international multicenter superiority RCT, initiated by the Dutch Pancreatic Cancer Group (DPCG). All patients with LAPC according to DPCG criteria, who start with FOLFIRINOX or (nab-paclitaxel/)gemcitabine, are screened for eligibility. Restaging is performed after completion of four cycles of FOLFIRINOX or two cycles of (nab-paclitaxel/)gemcitabine (i.e., 2 months of treatment), and the results are assessed within a nationwide online expert panel. Eligible patients with RECIST stable disease or objective response, in whom resection is not feasible, are randomized to RFA followed by chemotherapy or chemotherapy alone. In total, 228 patients will be included in 16 centers in The Netherlands and four other European centers. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, RECIST response, CA 19.9 and CEA response, toxicity, quality of life, pain, costs, and immunomodulatory effects of RFA. Discussion The PELICAN RCT aims to assess whether the combination of chemotherapy and RFA improves the overall survival when compared to chemotherapy alone, in patients with LAPC with no progression of disease following 2 months of systemic treatment. Trial registration Dutch Trial RegistryNL4997. Registered on December 29, 2015. ClinicalTrials.govNCT03690323. Retrospectively registered on October 1, 2018

Published
2021

20. Management of pancreatic fistula and biliary leakage after pancreatoduodenectomy through percutaneous transhepatic biliary drainage

Author

I.Q. Molenaar, D.A.F. vd Heuvel, W W Te Riele, O.M. van Delden, K.P. van Lienden, Jan Albert Vos, M. van Leersum, F.J. Smits, O.R.C. Busch, A.C. Henry, M.G. Besselink, M.J.L. van Strijen, and H.C. van Santvoort

Subjects
medicine.medical_specialty, Hepatology, business.industry, Pancreatic fistula, Endocrinology, Diabetes and Metabolism, Gastroenterology, Medicine, Percutaneous transhepatic biliary drainage, business, medicine.disease, Biliary leakage, Surgery
Published
2021

21. Nationwide trends in incidence, treatment and survival of patients with pancreatic cancer in the past two decades

Author

O.R.C. Busch, H.W.M. van Laarhoven, I.Q. Molenaar, L.G.M. van der Geest, Pauline A. J. Vissers, Bert A. Bonsing, J. Verheij, Johanna W. Wilmink, H.C. van Santvoort, G. van Tienhoven, N. Haj Mohammad, C.H.J. van Eijck, Anouk E J Latenstein, B. Groot Koerkamp, V. E. de Meijer, J. de Vos-Geelen, M.G. Besselink, and I.H.J.T. de Hingh

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Incidence (epidemiology), Pancreatic cancer, Gastroenterology, Medicine, business, medicine.disease
Published
2020

22. Practice variation in systemic chemotherapy for patients with metastatic pancreatic cancer: A population-based study

Author

G.J.M. Creemers, C.H.J. van Eijck, J. de Vos-Geelen, J.W.B. de Groot, A.J. ten Tije, Johanna W. Wilmink, I.Q. Molenaar, Anouk E J Latenstein, Marjolein Y.V. Homs, L.G.M. van der Geest, N. Haj Mohammad, Tara M. Mackay, H.W.M. van Laarhoven, and M.G. Besselink

Subjects
Population based study, Oncology, medicine.medical_specialty, Variation (linguistics), Hepatology, Systemic chemotherapy, business.industry, Internal medicine, Metastatic pancreatic cancer, Gastroenterology, medicine, business
Published
2020

23. Axial slicing versus bivalving of the pancreatic head in the pathological examination of pancreatoduodenectomy specimens (apollo): A randomized controlled trial

Author

M.G. Besselink, A. Farina Sarasqueta, K. Kuijpers, S. van Dieren, R. van der Post, Michail Doukas, Carolien Bronkhorst, Lianne Koens, O.R.C. Busch, H.C. van Santvoort, M.L.F. van Velthuysen, I.Q. Molenaar, S. van Roessel, B. Groot Koerkamp, E. Soer, M. Stommel, L. A. A. Brosens, C A Seldenrijk, J. Ve, and G M Raicu

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Gastroenterology, Apollo, biology.organism_classification, Pancreatic head, law.invention, Randomized controlled trial, law, Medicine, Radiology, business, Pathological
Published
2020

24. Early detection and minimally invasive management of complications reduces mortality after pancreatic resection: the nationwide stepped-wedge porsch trial

Author

D.J. Lips, O.M. van Delden, C. van der Leij, I.H.J.T. de Hingh, W.J.M. Derksen, R.M. van Dam, Bert A. Bonsing, M. den Dulk, Ihm Borel Rinkes, T.L. Bollen, Sebastiaan Festen, J. Hagendoorn, E. van der Harst, B.A. Zonderhuis, C.H.J. van Eijck, V. E. de Meijer, I.Q. Molenaar, Koop Bosscha, H van Werkhoven, M. van der Kolk, Adriaan Moelker, Daphne Roos, Mark J. Arntz, Gijs A. Patijn, F. Wit, W W Te Riele, O.R.C. Busch, H.C. van Santvoort, Jennifer M.J. Schreinemakers, K.P. van Lienden, A.C. Henry, Geert Kazemier, M.G. Besselink, van den Heuvel, Lois A. Daamen, J.S.D. Mieog, M. Stommel, M. Liem, B. Groot Koerkamp, and F.J. Smits

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Early detection, Stepped wedge, Medicine, business, Pancreatic resection, Surgery
Published
2021

25. Survival benefit of resection of locally advanced pancreatic cancer following upfront FOLFIRINOX versus FOLFIRINOX only treatment: a multicenter propensity score-matched analysis

Author

Johanna W. Wilmink, Frank J. Wessels, I.H.J.T. de Hingh, V. E. de Meijer, M. Stommel, Lois A. Daamen, M.G. Besselink, Sebastiaan Festen, Lilly J H Brada, D. Latifi, Chung Y. Nio, O.R.C. Busch, Rutger C G Bruijnen, L. Magermans, M. Liem, R. Van Dam, Marco B. Polee, B. Groot Koerkamp, C.H.J. van Eijck, K.P. van Lienden, H.C. van Santvoort, J. de Vries, I.Q. Molenaar, M.S. Walma, Gijs A. Patijn, and Koop Bosscha

Subjects
Oncology, medicine.medical_specialty, Survival benefit, Hepatology, business.industry, FOLFIRINOX, Internal medicine, Propensity score matching, Gastroenterology, Medicine, business, Resection, Locally advanced pancreatic cancer
Published
2021

26. First Experiences with Robotic versus Open Pancreatoduodenectomy: A Nationwide Retrospective Propensity-score Matched Analysis

Author

M.G. Besselink, I.Q. Molenaar, J. van Hilst, G. van der Schelling, M. Luyer, D.J. Lips, S. van Dieren, Peter Paul L. O. Coene, M. Stommel, Bert A. Bonsing, B. Groot Koerkamp, M. Abu Hilal, H.C. van Santvoort, N. de Graaf, and O.R.C. Busch

Subjects
medicine.medical_specialty, Hepatology, business.industry, Propensity score matching, Gastroenterology, Physical therapy, medicine, business
Published
2021

27. Global Outcomes and Learning Curve for Clinical Outcomes and Proficiency of Robotic Pancreatoduodenectomy

Author

O. Saint-Marc, R. F. de Wilde, L.R. Jones, I.Q. Molenaar, B. Shen, Hongbeom Kim, Ja-June Jang, Marcel Autran C. Machado, N. de Graaf, M. Luyer, M. Abu Hilal, Y.-S. Shan, Bert A. Bonsing, M.G. Besselink, Ugo Boggi, T. Hackert, Maurice J. W. Zwart, B. Groot Koerkamp, D.J. Lips, L. Moraldi, C.-M. Peng, C. Moo Kang, and Yi-Ming Shyr

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, medicine, Medical physics, business
Published
2021

28. Incidence of and Risk Factors for Chyle Leak after Pancreatic Resection: A Nationwide Analysis

Author

Anouk E J Latenstein, J. de Vos-Geelen, C.H. van Eijk, M.G. Besselink, I.Q. Molenaar, Bert A. Bonsing, S. Augustinus, O.R.C. Busch, H.C. van Santvoort, I.H.J.T. de Hingh, B. Groot Koerkamp, and V. E. de Meijer

Subjects
Leak, medicine.medical_specialty, Chyle, Hepatology, business.industry, Incidence (epidemiology), Gastroenterology, Medicine, business, Pancreatic resection, Surgery
Published
2021

29. Predictors of occult metastases during surgery in patients with resectable pancreatic and periampullary cancer

Author

Koop Bosscha, Frank J. Wessels, G. van der Schelling, F. Wit, O.R.C. Busch, M.S. Walma, Bert A. Bonsing, I.H.J.T. de Hingh, Sebastiaan Festen, H.C. van Santvoort, V. E. de Meijer, M. Stommel, Daphne Roos, R. Van Dam, Vincent B. Nieuwenhuijs, I.Q. Molenaar, M. Liem, B. Groot Koerkamp, M.G. Besselink, F.J. Smits, E. van der Harst, and Geert Kazemier

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Periampullary cancer, Medicine, In patient, Radiology, business, people, Occult, people.cause_of_death
Published
2020

30. C-reactive protein is superior to white blood cell count for early prediction of major complications after pancreatoduodenectomy

Author

H. Aziz, O.R.C. Busch, B. Groot Koerkamp, M.G. Besselink, J. Van Dongen, F.J. Smits, H.C. van Santvoort, I.Q. Molenaar, and C.H.J. van Eijck

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, C-reactive protein, Gastroenterology, medicine.anatomical_structure, Internal medicine, White blood cell, Early prediction, medicine, biology.protein, Major complication, business
Published
2020

31. Conditional survival after resection of pancreatic cancer: A population-based study

Author

Johanna W. Wilmink, B. Groot Koerkamp, Bert A. Bonsing, M. Stommel, Anouk E J Latenstein, O.R.C. Busch, Marjolein Y.V. Homs, M.G. Besselink, C.H.J. van Eijck, I.Q. Molenaar, R. Van Dam, V.E.P.P. Lemmens, Joost M. Klaase, L.G.M. van der Geest, H.W.M. van Laarhoven, and I.H.J.T. de Hingh

Subjects
Population based study, Oncology, medicine.medical_specialty, Hepatology, Conditional survival, business.industry, Internal medicine, Pancreatic cancer, Gastroenterology, Medicine, business, medicine.disease, Resection
Published
2020

32. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: A population-based analysis

Author

Anouk E J Latenstein, A.J. ten Tije, Tara M. Mackay, Marjolein Y.V. Homs, I.Q. Molenaar, G.J.M. Creemers, J.W.B. de Groot, H.W.M. van Laarhoven, L.G.M. van der Geest, N. Haj Mohammad, C.H.J. van Eijck, J. de Vos-Geelen, Johanna W. Wilmink, and Marc G. Besselink

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Pancreatic ductal adenocarcinoma, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, Gastroenterology, Medicine, Population based, business
Published
2020

33. Survival and complications of pancreatectomy following FOLFIRINOX chemotherapy in borderline resectable and locally advanced pancreatic cancer: A pan-European cohort

Author

Roberto Salvia, M. Abu Hilal, M Del Chiaro, B. Groot Koerkamp, E. van Veldhuisen, O.R.C. Busch, Mickael Lesurtel, Sjors Klompmaker, Quisette P. Janssen, O. Strobel, Claudio Bassi, Jörg Kleeff, Tobias Keck, I.Q. Molenaar, Johanna W. Wilmink, and M.G. Besselink

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Hepatology, business.industry, FOLFIRINOX, medicine.medical_treatment, Gastroenterology, Locally advanced pancreatic cancer, Pan european, Borderline resectable, Internal medicine, Pancreatectomy, Cohort, medicine, business
Published
2020

34. Outcome including long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study

Author

Anouk E J Latenstein, S. van Dieren, M.G. Besselink, Michael F. Gerhards, Bert A. Bonsing, Bobby K Pranger, I.H.J.T. de Hingh, Koop Bosscha, Joost M. Klaase, Geert Kazemier, E. van der Harst, Joris J. Scheepers, Peter Paul L. O. Coene, J. E. van Hooft, J. Erdmann, F. Snoek, H. DeVries, O.R.C. Busch, H. van Goor, C.H.J. van Eijck, S. Mieog, I.Q. Molenaar, Gijs A. Patijn, G. van der Schelling, Lianne Scholten, R.M. van Dam, and H.C. van Santvoort

Subjects
Pediatrics, medicine.medical_specialty, Quality of life, Panorama, Hepatology, Total pancreatectomy, business.industry, medicine, Gastroenterology, business, Outcome (game theory), Cohort study, Term (time)
Published
2020

35. Assessment of colorectal liver metastasis: results of the Dutch Colorectal Cancer Group (DCCG) liver metastases expert panel of the CAIRO5 study

Author

P.B. Olthof, C.J.A. Punt, K.P. van Lienden, T.M. van Gulik, M. G. H. van Oijen, J.H.W. de Wilt, Cees Verhoef, J. Huiskens, A. Rijken, Marc R. W. Engelbrecht, Gijs A. Patijn, M. Liem, T. Ruers, Michael F. Gerhards, Geert Kazemier, Astrid Keijser, John J. Hermans, Cornelius H. C. Dejong, I.Q. Molenaar, and K. de Jong

Subjects
Oncology, medicine.medical_specialty, Hepatology, Colorectal cancer, business.industry, Internal medicine, medicine, Gastroenterology, medicine.disease, business, Metastasis
Published
2019

36. The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases : A systematic review and meta-analysis

Author

M F J Seesing, M. A. A. J. van den Bosch, T.J.M. Ruers, Helena M. Verkooijen, Morsal Samim, P.S.N. Van Rossum, I.Q. Molenaar, I. H. M. Borel Rinkes, Marnix G.E.H. Lam, and R. van Hillegersberg

Subjects
RFA, medicine.medical_specialty, Review, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Primary outcome, medicine, Journal Article, Methodological quality, Accuracy, Quality assessment, business.industry, Disease progression, Treatment evaluation, Oncology, 030220 oncology & carcinogenesis, Meta-analysis, Hepatic metastases, Ablation Therapy, Fdg pet ct, Surgery, Radiology, business, Nuclear medicine, Nuclear imaging, Meta-Analysis
Abstract

Purpose Uncertainty exists regarding the optimal imaging modality for timely detection of disease progression (DP) after ablation therapy for colorectal liver metastases. We evaluated the diagnostic accuracy of 18 F-FDG PET(/CT), CT and MRI for detection of DP following ablation therapy. Methods A systematic search was performed on May 18, 2016. The analysis included studies that reported on the diagnostic accuracy of 18 F-FDG PET(/CT), CT and/or MRI for post-ablative evaluation of patients with liver metastases. Primary outcome was the diagnostic accuracy of the imaging modalities for detection of DP. Methodological quality was assessed using the QUADAS-2 tool. Pooled sensitivities and specificities were estimated using bivariate random-effects models. Results Ten studies were included in the meta-analysis, including seven comparative studies. Nine reported data on diagnostic accuracy of 18 F-FDG PET(/CT), seven on CT imaging. Only two studies reported the diagnostic accuracy of MRI, hence not included in the meta-analysis. Quality assessment raised concerns about the risk of bias regarding the use of the reference standard, blinding of the index tests and the follow-up time. Pooled sensitivity was respectively 84.6% (75.0–90.6) and 53.4% (29.0–76.4) for 18 F-FDG PET(/CT) and CT ( P = 0.005). Pooled specificity was respectively 92.4% (86.5–95.9) and 95.7% (87.5–98.6) ( P = 0.392). Conclusion 18 F-FDG PET/(CT) yields a higher sensitivity for detecting DP after ablation therapy compared with CT and has a comparably high specificity. These findings indicate that the use of 18 F-FDG PET(/CT) in this setting particularly allows for minimization of the false-negative rate compared with CT without compromising the low false-positive rate.

Published
2017

37. Radiofrequency ablation and irreversible electroporation in locally advanced pancreatic cancer: Competitive or complementary treatment modalities?

Author

Jantien A. Vogel, Krijn P. van Lienden, Hjalmar C. van Santvoort, Olivier R. Busch, Johanna W. Wilmink, I.Q. Molenaar, Marieke S. Walma, Marc G. Besselink, and Eran van Veldhuisen

Subjects
medicine.medical_specialty, Hepatology, business.industry, Radiofrequency ablation, Endocrinology, Diabetes and Metabolism, Gastroenterology, Irreversible electroporation, law.invention, Locally advanced pancreatic cancer, law, Treatment modality, Medicine, Radiology, business
Published
2018

38. Intraoperative fistula risk score (iFRS) in pancreatoduodenectomy: development and validation in three datasets

Author

R. Van Dam, D.J. Lips, Joris J. Scheepers, Michael F. Gerhards, C. Vollmer, Victor van Woerden, E.W. Steyerberg, V. Nieuwenhuis, B. Groot Koerkamp, Brett L. Ecker, Zaed Hamady, D. van Klaveren, Bert A. Bonsing, R. Linnemann, O.R.C. Busch, I.H.J.T. de Hingh, Coen G. Rupert, F.J. Smits, T. Armstrong, Joost M. Klaase, S. van Dieren, M.G. Besselink, M. Luyer, H. van Goor, M. Abu Hilal, Geert Kazemier, A. Takhar, E. van der Harst, J. Erdmann, K. de Jong, L.B. van Rijssen, I.Q. Molenaar, T H Mungroop, C.H.J. van Eijck, Salvatore Barbaro, Awad Shamali, G. van der Schelling, and H.C. van Santvoort

Subjects
medicine.medical_specialty, Framingham Risk Score, Hepatology, business.industry, General surgery, Fistula, Gastroenterology, medicine, medicine.disease, business
Published
2019

39. A prospective longitudinal study of the impact of pancreatic resection for malignancy on health related quality of life

Author

I.Q. Molenaar, Jeroen Hagendoorn, I. H. M. Borel Rinkes, M. van Vulpen, H.D. Heerkens, Menno R. Vriens, H.C. van Santvoort, Dorine S.J. Tseng, Gert J. Meijer, and Irene M. Lips

Subjects
Oncology, Health related quality of life, medicine.medical_specialty, Longitudinal study, Hepatology, business.industry, Internal medicine, medicine, Gastroenterology, Pancreatic resection, business, Malignancy, medicine.disease
Published
2016
Full Text
View/download PDF

41. The role of CT in assessment of extra-regional lymph node involvement in pancreatic and peri-ampullary cancer: A prospective diagnostic accuracy study

Author

I.Q. Molenaar, M. S. van Leeuwen, M.G. Besselink, H.C. van Santvoort, Dorine S.J. Tseng, G J A Offerhaus, and I. H. M. Borel Rinkes

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Peri, Gastroenterology, Diagnostic accuracy, macromolecular substances, Ampullary cancer, Regional lymph node involvement, Internal medicine, medicine, Radiology, business
Published
2016
Full Text
View/download PDF

42. Robot-assisted laparoscopic liver resection: First dutch experience

Author

Carolijn L.M.A. Nota, R. van Hillegersberg, I.Q. Molenaar, I. H. M. Borel Rinkes, and Jeroen Hagendoorn

Subjects
03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Hepatology, business.industry, 030220 oncology & carcinogenesis, General surgery, Gastroenterology, Robot, Medicine, 030211 gastroenterology & hepatology, business, Resection
Published
2016
Full Text
View/download PDF

45. PV-0321: MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer

Author

Onne Reerink, I.Q. Molenaar, C.A.T. Van den Berg, Gert J. Meijer, H.D. Heerkens, M.P.W. Intven, M. van Vulpen, Beth Erickson, and Frank P. Vleggaar

Subjects
Stereotactic radiotherapy, medicine.medical_specialty, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, Mri guided, Locally advanced pancreatic cancer
Published
2017

46. Isolated pulmonary recurrence following pancreatectomy for pancreatic cancer: the effect of patient factors and treatment modalities on survival

Author

Matthew J. Weiss, I.Q. Molenaar, Vincent P. Groot, Richard A. Burkhart, Alex B. Blair, Stephen C. Yang, Georgios Gemenetzis, C.L. Wolfgang, Jin He, and John L. Cameron

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, medicine.disease, Treatment modality, Internal medicine, Pancreatic cancer, Pancreatectomy, Medicine, business, Patient factors
Published
2018

47. Pancreatoduodenectomy should be avoided when para-aortic lymph node metastases are found during surgical exploration for suspected pancreatic ductal adenocarcinoma

Author

Gijs A. Patijn, Joost M. Klaase, Joris I. Erdmann, S. Ubels, V. E. de Meijer, Dorine S.J. Tseng, I. H. M. Borel Rinkes, J.H. Offerhaus, Bobby K Pranger, KP de Jong, I.Q. Molenaar, and V. Nieuwenhuis

Subjects
medicine.medical_specialty, Para-aortic lymph node, Pancreatic ductal adenocarcinoma, Hepatology, business.industry, Gastroenterology, Medicine, Radiology, business
Published
2018

48. Intra-operative ultrasound to determine resecability during surgical exploration of primary non-resectable pancreatic cancer following induction chemotherapy

Author

E. van Veldhuisen, M. S. van Leeuwen, L.B. van Rijssen, I.Q. Molenaar, Johanna W. Wilmink, K.P. van Lienden, M.G. Besselink, M.S. Walma, H.W.M. van Laarhoven, and O.R.C. Busch

Subjects
Resectable Pancreatic Cancer, medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Intra operative ultrasound, medicine, Induction chemotherapy, Radiology, business
Published
2018

50. Intra-operative ultrasound to determine resectability during surgical exploration of primary non-resectable pancreatic cancer following induction chemotherapy

Author

Hanneke W. M. van Laarhoven, Chung Y. Nio, Eran van Veldhuisen, L.B. van Rijssen, Olivier R. Busch, Hjalmar C. van Santvoort, Krijn P. van Lienden, Otto M. van Delden, Marc G. Besselink, Frank J. Wessels, I.Q. Molenaar, Lonneke S. Yo, Maarten S. van Leeuwen, Marieke S. Walma, Rutger C G Bruijnen, Nadia Haj Mohammad, Ignace H. J. T. de Hingh, Johanna W. Wilmink, and Jan J. J. de Vries

Subjects
Resectable Pancreatic Cancer, medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Gastroenterology, Intra operative ultrasound, Induction chemotherapy, Medicine, Radiology, business
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results